Abstract
The aim of this paper is to summarize the molecular effects of GCs on CYP as well as the available clinical evidence on drug--drug interactions (DDIs) between GCs and other drugs in which GCs influence the metabolism of other edicines through modifying CYP activity. We used the factographic database DRUGDEX along with bibliographic searches.
Expert opinion: Most of the literature reported CYP3A4 induction by GCs, but this was not proved in all research. As the onclusions on these DDIs are conflicting, there are several issues to be considered like the dosage of GCs, the length of GCs treatment and concomitant therapy, all of which can have an additive inducing effect.
Further, in designing a DDI study, crossover studies are preferred. A literature search of the abovementioned information resources provided dissimilar results.